Infection of Total Hip Joint Prosthesis Clinical Trial
Official title:
Prospective Intra-individual Comparison of 18F-FDG and 68Ga-citrate PET/CT in Symptomatic Total Hip Arthroplasty Patients
Total hip replacement is the well-established surgical method for treatment of hip osteoarthritis and related diseases. The outcome of the procedure is commonly satisfactory and most patients will not need any revision surgery. However, the procedure has its complications, including (1) periprosthetic infection, (2) mechanical loosening caused by wear particles and (3) adverse reaction caused by metal ions released from metal-on-metal bearing surfaces. The unsolved clinical problem is related to the differential diagnosis of these conditions. The purpose of this prospective clinical study is to compare the efficacy of two techniques of PET/CT imaging in the differential diagnosis of these complications. Positron Emission Tomography (PET)/Computed Tomography (CT) imaging, performed during a single day, will include the head-to-head comparison of 18F-Fluoro-D-Glucose (18F-FDG) PET/CT and 68Gallium-citrate (68Ga-citrate) PET/CT imaging.
(68Ga) gallium citrate is a novel PET tracer aimed for detection of skeletal infections. It
has not been previously applied to diagnose periprosthetic joint infections in arthroplasty
patients. This exploratory prospective study, representing the first of its kind, examines
the use of 68Ga-citrate as a diagnostic tool of periprosthetic infections aside with 18F-FDG
tracer as the standard reference.
The first study group (n=10) will include total hip replacement patients without infection.
The recruited patients should suffer from pain and/or functional impairment due to adverse
reaction to metal debris (ARMD) caused by metal-on-metal bearings. The diagnosis of ARMD
should be based on metal artifact reduction sequence magnetic resonance imaging (MARS-MRI).
The patients will undergo the same-day comparison of the two PET/CT tracers.
The second study group (n=10) will include total hip replacement patients with
bacteriologically confirmed periprosthetic joint infection. The third group (n=10) will
include patients with aseptic loosening of total hip prosthesis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02842684 -
Orthopedic Digital Planning for Total Hip Arthroplasties
|
N/A | |
Not yet recruiting |
NCT04993027 -
Topical Vancomycin for Infection Prophylaxis in TJA
|
Phase 2 | |
Recruiting |
NCT05369104 -
Phage Therapy in Prosthetic Joint Infection Due to Staphylococcus Aureus Treated With DAIR.
|
Phase 2 | |
Completed |
NCT01854138 -
Evaluating Advantages of Prevena After Hip and Knee Arthroplasty
|
N/A | |
Recruiting |
NCT01517737 -
Immunology of Failing Metal-on-Metal Hip Replacement
|
N/A |